




**Figure S1: Multi arm randomized phase-II trial design in Ewing sarcoma between 2005-2018 (7 trials).** *CT: Chemotherapy. VTC: Vincristine, Topotecan, Cyclophosphamide. TEMIRI: Temozolomide + Irinotecan. MAMS: Multi-Arm Multi-Stage.*



**Figure S2: Primary efficacy endpoints in Ewing sarcoma phase-II trials between 2005 and 2018 (A) In the 67 phase-II and 2 phase-II-III trials and (B) In the phase-II part of the 77 phase-I/II trials.**




**Figure S3: Patients accrued in Ewing Sarcoma Phase-II trials over time between 2005 and 2018, classified by the year of trial opening. A. In the 146 trials B. ES patients accrued in the 62 published early-phase trials.**

## Graphical conclusion

*Better understanding ES biology/ preclinical model*

### International trials



**Figure S4:** Graphical conclusion and proposals for future phase-I/II trials enrolling ES recurrent or refractory patients. *CT: Chemotherapy, MRD: minimal residual disease, TTT: treatment, Combo: combination.*